Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00895921 · ClinicalTrials.gov registry record · Phase 4

Examining the Effects of Antipsychotic Medications on Insulin Sensitivity

A Phase 4 study of Diabetes, sponsored by Veterans Medical Research Foundation.

Completed
Registry status
Phase 4
Development phase
30
Enrollment target
1
Study location

NCT00895921: Completed Phase 4 study of Diabetes, sponsored by Veterans Medical Research Foundation.

NCT00895921 is a Phase 4 study of Diabetes that has completed, run by Veterans Medical Research Foundation. The registered enrollment target is 30 participants, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00895921, a Phase 4 study of Diabetes, has completed, sponsored by Veterans Medical Research Foundation.

COMPLETED
Registry status
Phase 4
Development phase
30 participants
Enrollment target
1
Study location

Study Summary

This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.

Primary Outcome

Ratio of post-antipsychotic/pre-antipsychotic glucose disposition as measured using the hyperglycemic clamp technique. This method allows one to measure either how well an individual metabolizes glucose or how sensitive an individual is to insulin.

Conditions Studied

Interventions

  • DRUG Olanzapine
  • DRUG Aripiprazole

Study Locations (1)

California

  • VA San Diego Healthcare System - San Diego

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2008-11
Est. Completion 2010-06
Phase Phase 4

What the finished NCT00895921 record still lists

NCT00895921 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 3,028-participant average among 338 other Diabetes trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Diabetes appearing as the primary indexed condition, and to 2 interventions - of which Olanzapine is the first listed.

NCT00895921 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT00895921 about?

NCT00895921 is a clinical study titled "Examining the Effects of Antipsychotic Medications on Insulin Sensitivity". This study will examine the effects of two different antipsychotic medications on control of blood sugar in people who are at risk of diabetes but mentally healthy.

What is the current status of trial NCT00895921?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 30 participants. The study started on 2008-11. Estimated completion is 2010-06.

What conditions does trial NCT00895921 study?

This clinical trial studies the following conditions: Diabetes.

What interventions are being tested in trial NCT00895921?

The interventions under investigation include: Olanzapine (DRUG), Aripiprazole (DRUG).

Who is sponsoring clinical trial NCT00895921?

This trial is sponsored by Veterans Medical Research Foundation, which has 35 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00895921 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetes

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00895921's enrollment target sits among peer trials

30 281st of 338 higher than 51 of 338 other Diabetes trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00977977 · 30 participants · Phase 2

    Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy

  • NCT01459107 · 30 participants · Phase 2

    Human Upper Extremity Allotransplantation

  • NCT01666080 · 30 participants · NA

    Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)

  • NCT01720836 · 30 participants · Phase 1

    Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00895921, the US trial registry maintained by the National Library of Medicine. NCT00895921 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.